NEWTOWN, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in January:
The Demy-Colton Digital Medicine and Medtech Showcase 2021, which is being held virtually from January 11th-15th.
The H.C. Wainwright BioConnect Conference, which is being held virtually from January 11th-14th.
The Sidoti Winter 2021 Investor Conference, which is being held virtually from January 13th-14th.
The ICR Conference 2021, which is being held virtually from January 11th-14th.
Webcasts of the presentations will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Archives of the webcasts will be available for replay following the conference.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.
About the PoNS™ Device and PoNS Treatment™
The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”). The device is currently under review for clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
investorrelations@heliusmedical.com
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)…
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Neural Therapeutics Inc. ("Neural" or the "Company"),…
Charlotte, North Carolina--(Newsfile Corp. - June 27, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
Ranking includes factors such as diversity, culture, work-life balance, career opportunities CHICAGO, June 27, 2024…
All caregivers in the state can access free resources at home PIERRE, S.D., June 27,…
Infusyn Therapeutics will manufacture and supply the Prometra II pump currently serving the Pain and…